Answers are grounded in this paper and cite their sources.
A structure-activity relationship study was carried out on a series of thiohydantoins and their analogues 14 which led to the discovery of 92 (MDV3100) as the clinical candidate for the treatment of hormone refractory prostate cancer.
No takes yet. Share an insight, caveat, or question.
Jung et al. (2010) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: